The Role of Age and Exposure to Plasmodium falciparum in the Rate of Acquisition of Naturally Acquired Immunity: A Randomized Controlled Trial

Abstract

BackgroundThe rate of acquisition of naturally acquired immunity (NAI) against malaria predominantly depends on transmission intensity and age, although disentangling the effects of these is difficult. We used chemoprophylaxis to selectively control exposure to P. falciparum during different periods in infancy and explore the effect of age in the build-up of NAI, measured as risk of clinical malaria.Methods and FindingsA three-arm double-blind randomized placebo-controlled trial was conducted in 349 infants born to Mozambican HIV-negative women. The late exposure group (LEG) received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5–4.5 months of age and monthly placebo from 5.5–9.5 months; the early exposure group (EEG) received placebo from 2.5–4.5 months and SP+AS from 5.5–9.5 months; and the control group (CG) received placebo from 2.5–9.5 months. Active and passive case detection (PCD) were conducted from birth to 10.5 and 24 months respectively. The primary endpoint was time to first or only episode of malaria in the second year detected by PCD. The incidence of malaria during the second year was of 0.50, 0.51 and 0.35 episodes/PYAR in the LEG, EEG and CG respectively (p = 0.379 for the adjusted comparison of the 3 groups). The hazard ratio of the adjusted comparison between the LEG and the CG was 1.38 (0.83–2.28, p = 0.642) and that between the EEG and the CG was 1.35 (0.81–2.24, p = 0.743).ConclusionsAfter considerably interfering with exposure during the first year of life, there was a trend towards a higher risk of malaria in the second year in children who had received chemoprophylaxis, but there was no significant rebound. No evidence was found that the age of first exposure to malaria affects the rate of acquisition of NAI. Thus, the timing of administration of antimalarial interventions like malaria vaccines during infancy does not appear to be a critical determinant.Trial Registration ClinicalTrials.gov NCT00231452

Interleukin-10 (IL-10) Polymorphisms Are Associated with IL-10 Production and Clinical Malaria in Young Children

“…Written informed consent was obtained from all mothers. Analysis of the young children's cohort did not indicate significant effects of the controlled exposure on P. falciparum infection outcomes and immunity (5).…”

“…Their children were followed until they were 2 years of age, with the aim of investigating age of exposure and immunity to malaria in young children (5). The AgeMal study provided a unique opportunity to longitudinally investigate the potential effects of IL-10 on clinical malaria in young children.…”

Changing Trends inP. falciparumBurden, Immunity, and Disease in Pregnancy

“…The increases in prevalence between 2010 and 2012 without evident changes in malariacontrol efforts suggest that climate factors, as well as increasing mosquito and parasite resistance to insecticides and antimalarial agents, respectively, may have played a role. Although similar trends have been observed in malariarelated hospital admissions in the area, 33 it remains unclear whether health care facility-based trends in malaria among pregnant women who are targets of intensive preventive measures can be extrapolated to the general community.…”

Protective Efficacy and Safety of Three Antimalarial Regimens for the Prevention of Malaria in Young Ugandan Children: A Randomized Controlled Trial

“…Indeed, in the first study of IPTi with SP in Tanzania, SP showed the highest protective efficacy during the intervention, and there was a sustained reduction in the incidence of malaria in the year after the intervention was stopped, suggesting that IPTi could actually enhance the development of naturally acquired immunity [27]. In a more recent study from Mozambique, chemoprevention with monthly SP+AS between 2.5 and 4.5 mo of age or between 5.5 and 9.5 mo of age was highly effective and was associated with a trend towards a higher risk of malaria in the second year of life compared to children who had not received chemoprevention, but the differences were not statistically significant [28]. In this study, the incidence of malaria rose from 6 to 36 mo of age in the no chemoprevention arm, reaching a remarkably high level, suggesting the lack of acquisition of clinically significant naturally acquired immunity and/or a temporal increase in exposure.…”